FY2025 EPS Estimates for Krystal Biotech Cut by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS) – Cantor Fitzgerald cut their FY2025 earnings estimates for Krystal Biotech in a research report issued on Wednesday, May 7th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of $4.85 per share for the year, down from their prior forecast of $6.22. Cantor Fitzgerald has a “Overweight” rating and a $215.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million.

A number of other research firms have also commented on KRYS. Chardan Capital reissued a “buy” rating and issued a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday. Citigroup lifted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Guggenheim decreased their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a report on Wednesday. Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Tuesday. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $218.63.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $132.23 on Friday. The business’s 50-day simple moving average is $171.56 and its 200-day simple moving average is $170.06. Krystal Biotech has a 52 week low of $131.71 and a 52 week high of $219.34. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of 44.22 and a beta of 0.79.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds have recently modified their holdings of KRYS. Fifth Third Bancorp raised its stake in Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after acquiring an additional 105 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech during the 3rd quarter worth about $40,000. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech during the 4th quarter worth about $95,000. Covestor Ltd lifted its holdings in Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after purchasing an additional 642 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in Krystal Biotech during the fourth quarter worth about $119,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).